Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Executive Summary
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications
You may also be interested in...
Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol
With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients
Bristol’s Transformation To Biopharma Business Progresses With Adnexus Buy
Bristol-Myers Squibb is strengthening its investment in biotech treatments for cancer with its proposed acquisition of Adnexus Therapeutics
Bristol Is Confident In Abilify Acceptance By Physicians For Depression
Acceptance of Bristol-Myers Squibb's Abilify (aripiprazole) as adjunctive therapy for major depressive disorder may be eased by existing off-label use of the atypical antipsychotic in that market, according to the company